首页> 外文期刊>ABCD. Arquivos Brasileiros de Cirurgia Digestiva (So Paulo) >EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL
【24h】

EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL

机译:长期Roux-Zh-y胃旁路对大学医院肥胖手术服务体重和临床代谢合并的影响

获取原文
       

摘要

Background: Due to the high failure rate observed in the clinical treatment of morbid obesity an increase in bariatric surgery indications, as an alternative for the control of obesity and comorbidities, is noticeable. Aim: To evaluate the performance of type 2 diabetes mellitus, high blood pressure and dyslipidemia in patients submitted to Roux-en-Y gastric bypass in late follow-up. Methods: Retrospective analysis of 59 patients included in the bariatric surgery program. Anthropometric (height and body weight) and laboratory (LDLc, HDLc, VLDLc, triglyceride -TG - and glucose) data were collected on pre- and postoperative stages, through medical records. Results: Among the patients, 86% were female aged 43?±11, of whom 52% had attended high school. The average postoperative time was 7?±3 years. During the postoperative period, there were decreases of weight and body mass index, respectively (133?±06 kg vs 91?±04 kg p<0.05 e 49?±74 kg/m 2 vs 33?±79 kg/m 2 , p<0.05). In comparison to the preoperative stage, lower concentrations of glucose (101.00?±26.99 vs 89,11?±15.19, p=0.014), total cholesterol rates (179.00?±37,95 vs 167.48?±28,50, p=0.016), LDLc (104.30?±33.12 vs 91.46?±24.58, p=0.016), VLDLc (25.40?±11,12 vs 15.68?±7.40, p<0.01), and TG (143.35?±86.35 vs 82.45?±37.39, p<0.01) and higher concentrations of HDLc (43.53?±8.23 vs 57.90?±15.60, p<0.01) were identified in the postoperative stage. 40% of hypertensive patients were still undergoing high blood pressure treatment during the postoperative stage. There was remission of type 2 diabetes mellitus and dyslipidemia on 81% and 94% of the cases, respectively. Conclusion: Roux-en-Y gastric bypass has proven itself to be an effective long term procedure, promoting weight loss, remission of DM2 and dyslipidemia.
机译:背景:由于在病态肥胖的临床治疗中观察到的高衰竭率,增加肥胖手术指示的增加,作为控制肥胖症和合并症的替代方案是明显的。目的:评价2型糖尿病患者,高血压和血脂血症的表现,患者提交患者胃旁路的患者。方法:对肥胖症外科计划中包括59名患者的回顾性分析。通过医疗记录收集在预和术后和术后阶段的人体计量(高度和体重)和实验室(LDLC,HDLC,VLDLC,甘油三酯-TG和葡萄糖)数据。结果:患者中,86%是女性年龄43岁的女性,其中52%出席了高中。平均术后时间为7?±3年。在术后期间,分别减少重量和体重指数(133Ω±06 kg V​​s 91?±04 kg P <0.05 E 49?±74kg / m 2 Vs 33?±79 kg / m 2, P <0.05)。与术前阶段相比,较低浓度的葡萄糖(101.00?±26.99 Vs 89,11?±15.19,P = 0.014),总胆固醇率(179.00?±37,95 Vs 167.48?±28,50,P = 0.016 ),LDLC(104.30?±33.12 Vs 91.46?±24.58,P = 0.016),VLDLC(25.40?±11,12 Vs 15.68?±7.40,P <0.01)和TG(143.35?±86.35 Vs 82.45?±37.39术后阶段,术后鉴定了P <0.01)和较高浓度的HDLC(43.53±8.23 vs 57.90?±15.60,p <0.01)。 40%的高血压患者在术后阶段仍在进行高血压处理。在81%和94%的病例中分别存在2型糖尿病和血脂血症的缓解。结论:Roux-Zh-Y胃旁路已被证明是一种有效的长期程序,促进体重减轻,缓解DM2和血脂血症。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号